key: cord-0791634-dkl6labp
authors: Li, Shaoshuo; Shao, Yang; Chen, Hao; Wang, Jianwei
title: Using Network Pharmacology to Systematically Decipher the Potential Mechanisms of Jisuikang in the Treatment of Spinal Cord Injury
date: 2022-02-27
journal: Evid Based Complement Alternat Med
DOI: 10.1155/2022/4932153
sha: a2484a59bed53ee88c1122ca9802c9f823173f5c
doc_id: 791634
cord_uid: dkl6labp

OBJECTIVE: To identify the potential pharmacological targets of Jisuikang (JSK) for the treatment of spinal cord injury (SCI) using network pharmacology. METHODS: The bioactive compounds of JSK herbs and their corresponding potential SCI targets were obtained from three traditional Chinese medicine (TCM) databases. SCI-related therapeutic target genes were obtained from the Comparative Toxicogenomics Database and the GeneCards Database. The common target genes between the JSK compounds and SCI-related therapeutic targets were screened using GO/KEGG functional enrichment and protein-protein interaction (PPI) analyses to identify hub genes and their categories of biological function. Gene expression distribution and receiver operating characteristic curve (ROC) analyses were used to identify probable SCI-related target genes. Molecular docking was used to quantify molecular interactions between target genes and the bioactive compounds of JSK. RESULTS: A total of 183 JSK bioactive compounds and 197 target genes for the treatment of SCI were screened and assessed. The target genes were enriched primarily in drug metabolism and in inflammation-related biological processes. Ten genes with statistical significance were identified as therapeutic SCI-related target genes of JSK. Molecular docking experiments demonstrated that the proteins of these 10 genes docked with binding energies of less than −5 kcal/mol with the bioactive compounds in JSK. CONCLUSION: This study showed that the anti-SCI effects of JSK may be mediated through numerous bioactive components, multiple gene targets, and inflammation-related pathways and provided potential novel targets for directed therapies for treating SCI. These results provide a foundation for further experimental investigations into treatment options for SCI.

Spinal cord injury (SCI) can result in immediate and devastating impacts on motor function and other essential physiological functions [1] . e incidence of SCI in the United States is approximately 50 per million people per year, with over 17000 new cases reported every year [2] . e World Health Organization (WHO) estimates that between 250000 and 500000 people suffer from SCI each year [3] . SCI patients who survive the initial injury usually suffer multisystem trauma concomitant with SCI, contributing to significant risks of associated complications [4] . It is reported that the lifetime cost of treating SCI in the US ranges between $1.1 million and $4.7 million, and the total cost of caring SCI patients in the US exceeds $7 billion per year [2] . Although extensively studied and the understanding of their underlying pathophysiology has improved, effective clinical treatments for SCI are limited [5] . Because of this, complementary and alternative therapies have been increasingly used for treating SCI, especially traditional Chinese medicines (TCMs) [6] . TCM has been developing for over 2000 years and has a comprehensive theoretical system for disease diagnosis and prognosis [7] . TCM provides important guidelines for the treatment of numerous complicated diseases [7] . Jisuikang (JSK) is a clinical Chinese herbal formula developed using herbs described in TCM, which has shown satisfactory efficacy in several clinical trials comparing conventional SCI treatments [8] [9] [10] . JSK could significantly improve motor function and grades of spinal injury in patients after SCI, promoting the recovery and regeneration of nerve tissues. Wang et al. found that JSK promotes nerve cell regeneration by upregulating the expression of Nogo-A that reduces the growth of axotomized neurons after SCI [11, 12] . JSK was shown to increase neurotrophic factor expression, which promotes the recovery of neurological function in SCI rats [13] . Wu et al. showed that JSK improves motor function in SCI rats by inhibiting the NgR/RhoA/ ROCK signaling pathway [14] , indicating the potential of JSK to regenerate nerves. However, JSK is composed of a variety of Chinese herbs [8] , making it a challenge untangling the underlying molecular mechanisms of JSK in SCI recovery.

TCM therapy takes advantage of multiple herbal components, protein targets, and biological pathways, as well as their synergism, which complicates the identification of bioactive compounds, their biological targets, and their biological mechanisms [15] . Network pharmacology reveals the potential and complex interactions between compounds in Chinese herbs and targeted diseases by systematically investigating the "drug-gene-protein-disease" interaction network [16] [17] [18] . Network pharmacology integrates system biology, pharmacology, and computational biology and provides a systematic approach to studying how TCM regulates human biological networks [19] . Network pharmacology has discovered the bioactive compounds in Yinqiao and Xianlinggubao preparations that interact with candidate proteins and biological pathways for COVID-19 [20] and osteoporosis [21] , respectively.

In the present study, network pharmacology was used to screen and discover the bioactive compounds and the potential pharmacological mechanisms of JSK for the treatment of SCI. Gene expression analysis and molecular docking methods were used to verify the results of the network pharmacology analysis.

e workflow of this study is displayed in Figure 1 . [24] . e values for oral bioavailability (OB) and drug-likeness (DL) were set to >30% and >0.18 for screening candidate bioactive compounds [25] . All the bioactive compounds were annotated using the MOL IDs from TCMSP. Target genes of the bioactive compounds were obtained from TCMSP, and their official gene names were obtained from the UniProt Knowledgebase (UniProtKB, https://www.uniprot.org/).

e Human Gene Database (GeneCards, https://www.genecards.org/) [26] and the Comparative Toxicogenomics Database (CTD, http://ctdbase. org/) [27] were used to find potential therapeutic target genes for SCI using "spinal cord injury" as the search term.

Common Target Genes. Common target genes between JSK and SCI were identified using the VennDiagram package [28] in R 3.6.2 (https://www.r-project.org/). e interaction relationships between JSK bioactive compounds and the common target genes were determined, and an interaction network was constructed using Cytoscape software 3.8.2 (https://cytoscape.org/) [29] .

Gene Ontology (GO) enrichment analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis were performed to identify possible biological functions of the common target genes using the Database for Annotation, Visualization and Integrated Discovery 6.8 (DAVID 6.8, https://david.ncifcrf.gov/) [30] . e categories of cellular component, molecular function, and biological process were included in the GO terms. A false discovery rate (FDR) <0.05 was used to indicate significant differences among GO terms and KEGG pathways.

e Search Tool for the Retrieval of Interacting Genes (STRING V11, https://www.string-db.org/) [31] was used to construct a protein-protein interaction (PPI) network of the common target genes. e minimum required interaction score was set to 0.400. e PPI network was developed using Cytoscape.

e CytoNCA plugin for Cytoscape [32] was used to perform a topological network analysis that included betweenness centrality (BC), closeness centrality (CC), and degree centrality (DC) to identify hub genes among the common target genes.

Gene expression distribution and receiver operating characteristic (ROC) curves of the hub genes were generated and used to investigate the 2

Evidence-Based Complementary and Alternative Medicine association between the hub genes and prognoses in patients with SCI. e gene microarray dataset GSE151371 was downloaded from the Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo/) and provided the global gene expression in peripheral white blood cells from 10 healthy individuals without a history of SCI and 38 individuals who suffered traumatic SCI. e gene expression distributions and ROC curves of the identified hub genes between healthy individuals and the SCI individuals were assessed in these two groups to determine their probability as targets for treating SCI. Hub genes that displayed statistically significant differences (a BH-adjusted p < 0.05) and areas under the curve (AUC) > 0.7 in the ROC analysis were considered key genes relevant to possible treatments for SCI. Evidence-Based Complementary and Alternative Medicine

Genes. e structure files (PDB files) of the protein products of key genes identified through gene expression distribution and ROC analyses were obtained from the Protein Data Bank (PDB, https://www.rcsb.org/) [33] . AutoDockTools V1.5.6 (http://autodock.scripps.edu/) was used to remove excess ligands, water molecules, and protein chains from the protein structures and to add hydrogens to the proteins. Bioactive compounds of JSK that were correlated with proteins encoded by the hub genes were used as molecular ligands in the docking program. e molecular structure files of bioactive JSK compounds were acquired from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/), and Chem3D (https://www.codeweavers.com/) was used to construct the 3D models of the molecules (mol2 files). e PDB files of the target proteins and mol2 files of the bioactive compounds were converted into "PDBQT" formats using AutoDockTools. e docking coordinates were identified using the grid boxes in AutoDockTools. AutoDock Vina (http://vina.scripps.edu/) [34] was used to dock the molecular ligands to the corresponding proteins. e results of molecular docking experiments were analyzed and visualized using Discovery Studio 2016 and PyMOL (https://pymol.org/).

e number of bioactive compounds found in the herbs comprising JSK is shown in Table 1 . After removing duplicate compounds, a total of 183 JSK bioactive compounds were identified. ere were 233 potential target genes of these bioactive compounds identified. In addition, the search of the CTD and GeneCards databases identified 16184 and 6348 SCI-related target genes, respectively.

ere were 197 genes in common between JSK compound target genes and SCIrelated genes ( Figure 2 ). An interaction network analysis identified 359 nodes (1 herbal formula, 161 bioactive compounds, and 197 shared target genes) and 1632 edges ( Figure 3 ). According to the gene count, the top 15 bioactive compounds in the network are listed in Table 2 .

e GO terms most enriched in each category correlated to the bioactive compounds in JSK are listed in Figure 4 . e top 5 enriched GO terms were enzyme binding, positive regulation of transcription from RNA polymerase II promoter, response to drug, protein binding, and extracellular space. KEGG signaling pathway analysis revealed that most of the common target genes have associations with cancer and inflammation-related pathways (Table 3) .

e PPI network of common genes consisted of 197 nodes and 3829 edges. According to topological network analysis, PPI nodes are considered significant targets if the DC values were greater than twofold the median DC [35] . e median DC was set to a threshold >62 to identify significant nodes and generate a subnetwork. In the subnetwork, nodes where both BC and CC values were greater than their median (BC > 2.34, CC > 0.95) were further extracted as hub genes, and a new core network composed of hub genes was constructed ( Evidence-Based Complementary and Alternative Medicine

e results of the gene expression distribution of hub genes in the GSE151371 dataset (except EGFR, IL6, and MMP2, which were not in the GSE151371 dataset) show that 10 hub genes were downregulated in patients with SCI ( Figure 6 ). Expression levels of JUN, MAPK1, MAPK3, MMP9, STAT3, and VEGFA were higher in the SCI group than in the control group. ROC curves and associated AUC values of these hub genes are presented in Figure 7 . After combining the results of gene expression distributions and ROC curves, 10 key genes were found to have significant expression changes in SCI compared to the control: e protein products of the 10 key genes and the corresponding JSK compounds were chosen for molecular docking to assess their interactions.

e affinity binding energies between the target proteins and the bioactive compounds were calculated (Table 4 ). e efficacy of molecular docking is considered to be good if the affinity binding energy is <−5.0 kcal/mol. e docking results show that quercetin, luteolin, tanshinone IIA, and naringenin had strong binding energies with their corresponding SCI proteins. e molecular dockings of the best combination of key gene proteins and their corresponding JSK compounds are presented in Figure 8 .

Individuals might face decades with permanent SCI-related disabilities. Advances in understanding the pathological mechanism of SCI have improved clinical management strategies for treating SCI, decreasing morbidity, and improving functional outcomes in patients with SCI [1] . However, randomized clinical trials have not demonstrated the efficacy and safety of conventional reparatory therapies for the recovery of motor function in SCI patients. TCM therapies, including JSK, Buyang Huanwu decoction, and Governor Vessel electroacupuncture, have provided varying degrees of therapeutic results for SCI [8, 36, 37] . e TCM theory describes the pathogenesis of SCI as a "deficiency of kidney governor, stasis of governor pulse, and dereliction of duty of cardinal command." JSK was developed to investigate its effects in the treatment of SCI. According to TCM, the herbal compounds of JSK have the following therapeutic effects: Huangqi tonifies Qi and nourishes blood; Cheqianzi, Fuling, and Zexie help invigorate the spleen to treat diuresis; Roucongrong, Yinyanghuo, and Yizhi warm the kidney and strengthen Yang; Houpo and Zhishi regulate Qi to relieve pain; Chishao, Chuanxiong, Dahuang, Danggui, Danshen, Tubiechong, and Wugong activate blood circulation, ameliorating stasis and dredging meridians. Clinical studies have shown that JSK treatment provides significant improvement in functional recovery and the quality of life of SCI patients. However, the complex herbal composition and synergistic effects of JSK complicate the discovery of the specific mechanisms of JSK compounds for the treatment of SCI. We performed network pharmacology analysis to discover the potential bioactive compounds, biological targets, and molecular processes of JSK therapy for SCI.

e bioactive compounds in JSK are quercetin, luteolin, kaempferol, tanshinone IIA, nobiletin, baicalein, 7-O-methylisomucronulatol, anhydroicaritin, beta-sitosterol, formononetin, naringenin, C-Homoerythrinan, 1,6-didehydro-3,15,16-trimethoxy-, (3.beta.)-, miltionone I, stigmasterol, and isorhamnetin ( Table 2) . Quercetin protects the spinal cord and regulates secondary oxidative stress in SCI rats by inhibiting the activation of the p38MAPK/iNOS signaling pathway [38] . By activating the Nrf2/glutamate-cysteine ligase pathway, luteolin shows antioxidant, anti-inflammatory, and neuroprotective effects against SCI [39, 40] . Kaempferol reduces oxidative stress and inflammatory responses in SCI by inhibiting the MAPKs-NF-κB and pyroptosis signaling pathways [41] . Tanshinone IIA improves functional recovery after SCI-induced lower urinary tract dysfunction [42] . Baicalein contributes to the functional recovery of SCI by dampening pyroptosis and alleviating endoplasmic reticulum stress-mediated apoptosis [43] . ese studies support our findings of the bioactive compounds in JSK and their therapeutic role in SCI.

GO enrichment analysis revealed that the common genes were involved in regulation of transcription, enzyme binding and protein binding, response to drug, and extracellular space, indicating that the therapeutic effects of JSK may be associated with transcriptional regulation of target genes, drug metabolism, and various cell metabolic pathways. KEGG pathway analysis revealed that JSK might produce anti-SCI effects via multiple signaling pathways, including those in cancer, and the TNF, HIF-1, Toll-like receptor, and PI3K-Akt signaling pathways. e inflammatory response of nerve cells potentiates SCI damage and hinders functional recovery after SCI [44] . e PI3K-Akt pathway regulates regeneration of SCI in rats by attenuating the inflammatory response [45] . Hypoxia-inducible factor-1 (HIF-1) was found to reduce inflammation in SCI via miR-380-3p/ Evidence-Based Complementary and Alternative Medicine NLRP3 and Circ 0001723 [46] . TNF was identified from a different network analysis as a major hub for inflammation following SCI [47] . In addition, certain drugs used to treat SCI are highly associated with TNF-related pathways.

Overall, our results are consistent with these studies, indicating that JSK may exert anti-SCI effects through the above pathways. We identified 19 proteins from hub genes using PPI network analysis and confirmed that 10 were associated with JSK compounds in the treatment of SCI (CCND1, CXCL8, FOS, JUN, MAPK3, MMP9, MYC, PTGS2, TP53, and VEGFA).

e affinity values of all docking results were calculated to be less than −5.0 kcal/mol, indicating acceptable binding affinities between the 10 key proteins and the corresponding compounds in JSK. Our findings are consistent with numerous investigations linking proteins and pathways to SCI. Epigenetic silencing of CCND1 in bone marrow-derived mesenchymal stem cells provides protective effects and accelerates SCI repair in rats [48] . ere is evidence indicating that inhibition of the MAPK3/MAPK1 pathway could reduce inflammation and tissue injury in mice with SCI [49] . Activation of the cannabinoid-2 receptor attenuates neurological deficits in SCI by inhibiting MMP9 expression [50] . e transcription factor p53 plays an Evidence-Based Complementary and Alternative Medicine important role in regulating the regeneration and functional recovery of axons after SCI [51] . e astrocytes with dysregulated CXCL8 display restored sensitivity to inflammatory stimuli following spinal cord lesion, suggesting that CXCL8 contributes to the regulation of astrocyte-mediated inflammation [52] . MiR-152 inhibits inflammatory responses and promotes the recovery of the SCI in mice through the c-jun N-terminal kinase pathway [53] . Inhibition of miR-17-5p upregulates the expression of VEGFA in mesenchymal stem cells (MSCs) and promotes the angiogenic ability of MSCs to repair SCI [54] .

is study uncovered the multiple bioactive compounds, multiple target genes, and multiple pathways characteristics of JSK in the treatment of SCI. e above analysis results have given a general direction for research related to TCM therapy for SCI.

ere are limitations associated with the present study. Direct experimental validation of our findings is lacking, although our results are consistent with findings from other studies. In addition, all 

Based on a combination of network pharmacology approach, gene expression validation, and molecular docking, we uncovered potential genes, proteins, and molecular pathways potentially regulated by JSK compounds for the treatment of SCI. Key bioactive compounds of JSK against SCI include quercetin, luteolin, kaempferol, tanshinone IIA, 7-O-methylisomucronulatol, and nobiletin. Ten genes were identified as important therapeutic SCI-related target genes of JSK, including CCND1, CXCL8, FOS, JUN, MAPK3, MMP9, MYC, PTGS2, TP53, and VEGFA. In addition, we demonstrated that JSK might provide therapeutic effects for SCI by regulating the pathways associated with reducing inflammatory response and regenerating nerve cells, including TNF, HIF-1, Toll-like receptor, and PI3K-Akt signaling pathways. is study provides additional insights into TCM therapies for treating SCI and lays a foundation for further experimental studies.

AKT serine/threonine kinase 1 CASP3: Caspase 3 CCND1: Cyclin D1 CXCL8: C-X-C motif chemokine ligand 8 EGF:

Epidermal growth factor EGFR: Dermal growth factor receptor FOS:

Proto-oncogene GO:

Gene ontology IL6:

Interleukin 6 JUN:

Jun proto-oncogene KEGG: Kyoto Encyclopedia of Genes and Genomes MAPK1: Mitogen-activated protein kinase 1 MAPK3: Mitogen-activated protein kinase 3 MAPK8: Mitogen-activated protein kinase 8 MMP2: Matrix metallopeptidase 2 MMP9: Matrix metallopeptidase 9 MYC:

MYC proto-oncogene PPI:

Protein-protein interaction PTGS2: Prostaglandin-endoperoxide synthase 2 ROC:

Receiver operating characteristic curve SCI:

Spinal cord injury STAT3: Signal transducer and activator of transcription 3 TCM:

Traditional Chinese medicine TP53:

Tumor protein p53 VEGFA: Vascular endothelial growth factor A.

Data Availability e data used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

e authors declare that they have no conflicts of interest regarding the publication of this paper. Evidence-Based Complementary and Alternative Medicine

Spinal cord repair: advances in biology and technology

Spinal cord injury (SCI) 2016 facts and figures at a glance

A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope

Trauma:Spinal cord Injury

Modern medical management of spinal cord injury

Research progress in use of traditional Chinese medicine for treatment of spinal cord injury

Data mining and systematic pharmacology to reveal the mechanisms of traditional Chinese medicine in mycoplasma pneumoniae pneumonia treatment

Effect of Jisuikang (脊髓康) on kinetic dysfunction in patients after spinal injury

28 cases of spinal cord injury treated with Jisuikang

Jisuikang in the treatment of 19 cases of dysuria after spinal cord injury

Nogo-A expression dynamically varies after spinal cord injury

Effects of Jisuikang on Nogo-NgR gene expression in spinal cord rats with injury

Jisuikang, a Chinese herbal formula, increases neurotrophic factor expression and promotes the recovery of neurological function after spinal cord injury

Jisuikang promotes the repair of spinal cord injury in rats by regulating NgR/RhoA/ROCK signal pathway

Network pharmacology:New guidelines for drug discovery

Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology

Identified the synergistic mechanism of drynariae rhizoma for treating fracture based on network pharmacology

Network pharmacology: the next paradigm in drug discovery

A network pharmacology approach to explore active compounds and pharmacological mechanisms of epimedium for treatment of premature ovarian insufficiency

Exploring the treatment of COVID-19 with yinqiao powder based on network pharmacology

Deciphering the underlying mechanism of Xianlinggubao capsule against osteoporosis by network pharmacology

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine

ETCM: an encyclopaedia of traditional Chinese medicine

Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods

e GeneCards suite: from gene data mining to disease genome sequence analyses

CTD anatomy: analyzing chemical-induced phenotypes and exposures from an anatomical perspective, with implications for environmental health studies

VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R

Cytoscape: a software environment for integrated models of biomolecular interaction networks

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

STRING v10: Protein-protein interaction networks, integrated over the tree of life

CytoNCA: a cytoscape plugin for centrality analysis and evaluation of Evidence-Based Complementary and Alternative Medicine 13 protein interaction networks

e RCSB protein data bank:integrative view of protein, gene and 3D structural information

AutoDock Vina:Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Systematic understanding of the mechanism of baicalin against ischemic stroke through a network pharmacology approach

Buyang huanwu decoction combined with BMSCs transplantation promotes recovery after spinal cord injury by rescuing axotomized red nucleus neurons

Governor vessel electroacupuncture promotes the intrinsic growth ability of spinal neurons through activating calcitonin gene-related peptide/ α-calcium/calmodulin-dependent protein kinase/neurotrophin-3 pathway after spinal cord injury

Antioxidant effect of quercetin against acute spinal cord injury in rats and its correlation with the p38MAPK/iNOS signaling pathway

Neuroprotective effects of luteolin against spinal cord ischemia-reperfusion injury by attenuation of oxidative stress, inflammation, and apoptosis

Luteolin modulates the NF-E2-related factor 2/glutamate-cysteine ligase pathway in rats with spinal cord injury

Pretreatment with kaempferol attenuates microglia-mediate neuroinflammation by inhibiting MAPKs-NF-κB signaling pathway and pyroptosis after secondary spinal cord injury

Tanshinone IIA improves functional recovery in spinal cord injury-induced lower urinary tract dysfunction

Baicalein attenuates pyroptosis and endoplasmic reticulum stress following spinal cord ischemiareperfusion injury via autophagy enhancement

Spinal cord injury scarring and inflammation:therapies targeting glial and inflammatory responses

e PI3K/Akt/ FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-α and p27kip1 expression

Hypoxia inducible factor-1 (HIF-1α) reduced inflammation in spinal cord injury via miR-380-3p/ NLRP3 by Circ 0001723

Network analysis reveals TNF as a major hub of reactive inflammation following spinal cord injury

Protective effect of epigenetic silencing of cyclinD1 against spinal cord injury using bone marrow-derived mesenchymal stem cells in rats

Evidence for the role of mitogen-activated protein kinase signaling pathways in the development of spinal cord injury

Exogenous activation of cannabinoid-2 receptor modulates TLR4/MMP9 expression in a spinal cord ischemia reperfusion rat model

e MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury

Adult astrocytes from reptiles are resistant to proinflammatory activation via sustaining Vav1 expression

miR-152 promotes spinal cord injury recovery via c-jun amino terminal kinase pathway

Inhibition of miR-17-5p promotes mesenchymal stem cells to repair spinal cord injury

is study was supported by grants from the Science and Technology Development Program of TCM of Jiangsu Province (YB2020042) and the Wuxi Science and Technology Bureau Project (SKJJZD19). e authors greatly appreciated TopEdit (https://www.topeditsci.com) for the linguistic assistance during the preparation of this manuscript.